Danielle Cohen

Danielle Cohen

Auto-generated profile, based on publicly available information

Danielle Cohen

Department of Pathology, Leiden University Medical Center (LUMC), Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Kidney International
Verified
Journal Article
Open access
PDF file
DCDanielle Cohen
Danielle Cohen
RCRobert B. Colvin
Robert B. Colvin
MDMohamed R. Daha
Mohamed R. Daha
CDCinthia B. Drachenberg
Cinthia B. Drachenberg
MHMark Haas
Mark Haas
IBIngeborg M. Bajema
Ingeborg M. Bajema
The introduction of C4d in daily clinical practice in the late nineties aroused an ever-increasing interest in the role of antibody-mediated mechanisms in allograft rejection. As a marker of classical complement activation, C4d made it possible to visualize the direct link between anti-donor antibodies and tissue injury at sites of antibody binding in a graft. With the expanding use of C4d worldwide several limitations of C4d were identified. For instance, in ABO-incompatible transplantations C4d is present in the majority of grafts but this seems to point at ‘graft accommodation’ rather than antibody-mediated rejection. C4d is now increasingly recognized as a potential biomarker in other fields where antibodies can cause tissue damage, such as systemic autoimmune diseases and pregnancy. In all these fields, C4d holds promise to detect patients at risk for the consequences of antibody-mediated disease. Moreover, the emergence of new therapeutics that block complement activation makes C4d a marker with potential to identify patients who may possibly benefit from these drugs. This review provides an overview of the past, present, and future perspectives of C4d as a biomarker, focusing on its use in solid organ transplantation and discussing its possible new roles in autoimmunity and pregnancy.

1 June 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
DCDanielle Cohen
Danielle Cohen
LHLiesbeth M. Hondelink
Liesbeth M. Hondelink
NSNienke Solleveld-Westerink
Nienke Solleveld-Westerink
SUSandra M. Uljee
Sandra M. Uljee
DRDina Ruano
Dina Ruano
TWTom van Wezel
Tom van Wezel
Frequently, patients with locally advanced or metastatic NSCLC are screened for mutations and fusions. In most laboratories, molecular workup includes a multitude of tests: immunohistochemistry (ALK, ROS1, and programmed death-ligand 1 testing), DNA sequencing, in situ hybridization for fusion, and amplification detection. With the fast-emerging new drugs targeting specific fusions and exon-skipping events, this procedure harbors a growing risk of tissue exhaustion. In this study, we evaluated the benefit of anchored, multiplexed, polymerase chain reaction-based targeted RNA sequencing (RNA next-generation sequencing [NGS]) in the identification of gene fusions and exon-skipping events in patients, in which no pathogenic driver mutation was found by DNA-based targeted cancer hotspot NGS (DNA NGS). We analyzed a cohort of stage IV NSCLC cases from both in-house and referral hospitals, consisting 38.5% cytology samples and 61.5% microdissected histology samples, mostly core needle biopsies. We compared molecular findings in a parallel workup (DNA NGS and RNA NGS, cohort 1, n = 198) with a sequential workup (DNA NGS followed by RNA NGS in selected cases, cohort 2, n = 192). We hypothesized the sequential workup to be the more efficient procedure. In both cohorts, a maximum of one oncogenic driver mutation was found per case. This is in concordance with large, whole-genome databases and suggests that it is safe to omit RNA NGS when a clear oncogenic driver is identified in DNA NGS. In addition, this reduced the number of necessary RNA NGS to only 53% of all cases. The tumors of never smokers, however, were enriched for fusions and exon-skipping events (32% versus 4% in former and current smokers, p = 0.00), and therefore benefited more often from the shorter median turnaround time of the parallel approach (15 d versus only 9 d in the parallel workup). We conclude that sequentially combining DNA NGS and RNA NGS is the most efficient strategy for mutation and fusion detection in smoking-associated NSCLC, whereas for never smokers we recommend a parallel approach. This approach was shown to be feasible on small tissue samples including for cytology tests, can drastically reduce the complexity and cost of molecular workup, and also provides flexibility in the constantly evolving landscape of actionable targets in NSCLC.

10 March 2011 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
DCDanielle Cohen
Danielle Cohen
ABAletta Buurma
Aletta Buurma
NGNatascha N Goemaere
Natascha N Goemaere
GGGuillermina Girardi
Guillermina Girardi
SCSaskia le Cessie
Saskia le Cessie
IBIngeborg M Bajema
Ingeborg M Bajema

14 May 2010 in BMJ
Verified
Journal Article
Closed access
DCDanielle Cohen
Danielle Cohen
SBStefan P Berger
Stefan P Berger
GSGerda M Steup-Beekman
Gerda M Steup-Beekman
KBKitty W M Bloemenkamp
Kitty W M Bloemenkamp
IBIngeborg M Bajema
Ingeborg M Bajema

30 July 2008 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
DCDanielle Cohen
Danielle Cohen
MKMarije Koopmans
Marije Koopmans
IHIdske C. L. Kremer Hovinga
Idske C. L. Kremer Hovinga
SBStefan P. Berger
Stefan P. Berger
MGMarian Roos van Groningen
Marian Roos van Groningen
IBIngeborg M. Bajema
Ingeborg M. Bajema
Objective: In patients with systemic lupus erythematosus (SLE) and lupus nephritis, the presence of antiphospholipid antibodies (aPL) is considered to be an indication of increased risk of thrombotic microangiopathy, a serious complication of SLE. Previous studies have demonstrated a critical role for activation of the classical pathway of complement that leads to thrombotic injury in the presence of aPL. This study was undertaken to investigate whether C4d deposition in lupus nephritis is related to circulating aPL and the presence of renal microthrombi.Methods: Deposition patterns of C4d in 44 renal biopsy samples obtained from 38 patients with biopsy‐proven lupus nephritis were determined by staining with a polyclonal anti‐C4d antibody. A phosphotungstic acid–hematoxylin stain was used to identify fibrin microthrombi. Clinical data (serum creatinine levels and presence or absence of aPL) were obtained and correlated with findings in the renal biopsy specimens. Patients were categorized as having aPL (n = 20) or not having aPL (n = 18).Results: A strong relationship between the intensity of glomerular C4d staining and the presence of microthrombi was found (P < 0.002). Intense glomerular C4d deposition was present in 7 of 8 biopsy samples showing renal microthrombi. Neither C4d deposition nor the presence of microthrombi was correlated with aPL status.Conclusion: Our findings suggest that activation of the classical pathway of complement plays a pathogenic role in the development of renal tissue injury leading to thrombosis, irrespective of the type of circulating antibodies present. Immunodetection of glomerular C4d deposition in renal biopsy samples could be a convenient method of identifying patients at risk of thrombotic microangiopathy.

11 November 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
O(on behalf of the Dutch Breast Cancer Research Group (BOOG)
on behalf of the Dutch Breast Cancer Research Group (BOOG)
RLRieneke Lugtenberg
Rieneke Lugtenberg
SDStefanie deGroot
Stefanie deGroot
AKAd A. Kaptein
Ad A. Kaptein
MFMaarten J. Fischer
Maarten J. Fischer
Judith KroepJudith Kroep
Judith Kroep
Purpose: In the phase II DIRECT study a fasting mimicking diet (FMD) improved the clinical response to neoadjuvant chemotherapy as compared to a regular diet. Quality of Life (QoL) and illness perceptions regarding the possible side effects of chemotherapy and the FMD were secondary outcomes of the trial. Methods: 131 patients with HER2-negative stage II/III breast cancer were recruited, of whom 129 were randomly assigned (1:1) to receive either a fasting mimicking diet (FMD) or their regular diet for 3 days prior to and the day of neoadjuvant chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) questionnaires EORTC-QLQ-C30 and EORTC-QLQ-BR23; the Brief Illness Perception Questionnaire (BIPQ) and the Distress Thermometer were used to assess these outcomes at baseline, halfway chemotherapy, before the last cycle of chemotherapy and 6 months after surgery. Results: Overall QoL and distress scores declined during treatment in both arms and returned to baseline values 6 months after surgery. However, patients’ perceptions differed slightly over time. In particular, patients receiving the FMD were less concerned and had better understanding of the possible adverse effects of their treatment in comparison with patients on a regular diet. Per-protocol analyses yielded better emotional, physical, role, cognitive and social functioning scores as well as lower fatigue, nausea and insomnia symptom scores for patients adherent to the FMD in comparison with non-adherent patients and patients on their regular diet. Conclusions: FMD as an adjunct to neoadjuvant chemotherapy appears to improve certain QoL and illness perception domains in patients with HER2-negative breast cancer. Trialregister ClinicalTrials.gov Identifier: NCT02126449.